BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Closes $10.2M Private Placement

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, has closed its previously announced private placement to institutional and accredited investors. According to the update, the company sold 1,321,132 shares of its common stock at a purchase price of $7.75 per share for $10.2 million in the private placement. Processa Pharmaceuticals secured net proceeds of $9.9 million, which will enable the company to be funded through 2023 and either expand the clinical development of PCS6422 or conduct enabling toxicology studies to advance PCS11T. “We are grateful for the support from our investors. This financing will not only strengthen our balance sheet but will allow us to further develop one of our cancer treatment drugs, PCS6422 or PCS11T,” said David Young, Pharm.D., Ph.D., chairman and CEO of Processa Pharmaceuticals. “We anticipate that these two drugs will prove to be better than many of the present treatments in patients with colorectal cancer, breast cancer, pancreatic cancer or lung cancer.”

To view the full press release, visit https://ibn.fm/vYTsq

About Processa Pharmaceuticals Inc.

The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with unmet or underserved medical conditions who need treatment options that improve survival and/or quality of life. The company used these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently. Active pipeline programs include: PCS6422 (metastatic colorectal cancer and breast cancer), PCS499 (ulcerative necrobiosis lipoidica) and PCS12852 (GI motility/gastroparesis). The members of the Processa development team have been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and more than 100 FDA meetings throughout their careers. For more information, visit the company’s website at www.ProcessaPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at https://ibn.fm/PCSA

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork